TARDBP and amyotrophic lateral sclerosis: Prospective studies in larger, autopsy- or genetically confirmed, and multicenter cohorts integrating blood-based and TDP-43-related biomarkers and assessing longitudinal trajectories from presymptomatic stages to ALS–ALS/FTD overlap will be essential to validate and extend this multimodal framework.